Spark Biomedical Accelerates Women's Health Innovations
Innovative Funding for Women's Health by Spark Biomedical
Spark Biomedical, the parent organization of OhmBody, has recently made headlines with its selection for funding from Wellcome Leap as part of their impactful women's health initiative known as The Missed Vital Sign. This funding opportunity is a significant endorsement of Spark Biomedical's commitment to transforming women’s healthcare through cutting-edge medical technology.
Focus on Heavy Menstrual Bleeding
As part of its award-winning efforts, Spark Biomedical is directing its resources toward addressing heavy menstrual bleeding (HMB). They are leveraging a groundbreaking transcutaneous auricular neurostimulation (tAN) platform to provide an effective solution. This approach is noteworthy for its non-invasive nature, utilizing neurostimulation to engage the nervous system in a way that improves platelet function, ultimately reducing the intensity of menstruation.
Clinical Trials and Groundbreaking Results
The newly acquired funding empowers Spark Biomedical to initiate a nationwide clinical trial aiming to ascertain the safety and efficacy of tAN for women suffering from HMB and associated conditions like von Willebrand Disease (VWD). The upcoming clinical trial will focus on enrolling adult women with both HMB and VWD, alongside adolescents experiencing HMB without a known cause. With previous studies showing promising results, participants have experienced significant reduction in blood loss—over 50%—and about 20% shorter menstrual periods through the consistent use of tAN therapy.
A Commitment to Women's Health
Daniel Powell, President & CEO at Spark Biomedical, expressed pride in their funding selection, noting the honor of being part of a choice group among distinguished academic institutions. This acknowledgment not only emphasizes their innovative approach but also highlights their dedication to enhancing women's health through novel treatments.
Dr. Navid Khodaparast, Co-founder & Chief Science Officer, echoed these sentiments, stressing the importance of addressing the long-overlooked area of women's health. The funding will catalyze clinical trials of their pioneering neurostimulation device, which aims to provide an unprecedented non-invasive treatment for women experiencing HMB, with the prospect of gaining FDA approval.
Partnerships and Community Impact
Spark Biomedical is eager to collaborate with Wellcome Leap to expedite advancements in menstrual health solutions and improve the life quality for women globally affected by HMB. By focusing on the needs of women's health, Spark Biomedical is presenting a path towards meaningful solutions that could vastly improve clinical outcomes.
About Spark Biomedical
Founded with the mission to transform the medical landscape, Spark Biomedical is a prominent U.S.-based medical device developer. Their focus on bioelectronic medicine allows them to offer novel wearable neurostimulation solutions tailored to various health needs including neurological health, women's wellness, and hemostasis. With a deep commitment to advancing healthcare, they leverage expertise in neuroscience and engineering. By partnering with federal and academic institutions, they aim to empower healthcare providers with innovative strategies designed to tackle intricate medical challenges.
About OhmBody
OhmBody stands at the forefront of innovation in women’s wellness, part of Spark Biomedical’s wider vision. Their efforts emphasize the importance of understanding female-specific health needs and creating tailored solutions. Utilizing advanced wearable neurostimulation, OhmBody seeks to enhance menstrual health, blending scientific rigor with personal experience to drive change.
Contact Information
For any media inquiries related to Spark Biomedical or OhmBody, please reach out to:
Erika Siemasko
FACTEUR PR for OhmBody
ohmbody@facteurpr.com
978-270-2777
Frequently Asked Questions
What is the purpose of the funding Spark Biomedical received?
The funding aims to support clinical trials for their innovative neurostimulation technology to treat heavy menstrual bleeding.
What is transcutaneous auricular neurostimulation (tAN)?
tAN is a non-invasive method that stimulates the nervous system to improve platelet function and reduce menstrual bleeding.
Who can participate in the upcoming clinical trial?
The trial will enroll adult women with heavy menstrual bleeding, especially those with von Willebrand Disease, and adolescents with unexplained heavy menstrual bleeding.
What outcomes have early studies reported?
Initial studies indicate over 50% reductions in blood loss and 20% shorter menstrual periods for users of daily tAN therapy.
How is Spark Biomedical contributing to women's health?
They focus on developing groundbreaking medical technologies that address significant women’s health issues, like heavy menstrual bleeding, through innovative solutions.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.